Scopia Capital Management

Scopia Capital Management is an institutional alternative asset management firm that focuses on a fundamentals-based, value-driven investment approach. The company offers a diverse range of fund products that span various equity strategies, including long-short equity strategies managed with market neutrality and net long exposure, as well as a long-only equity strategy. Through its disciplined investment methodology, Scopia Capital aims to deliver value to its clients by leveraging thorough analysis and market insights in its investment decisions.

Matthew Sirovich

Founder and Managing Partner

4 past transactions

PM Pediatric Care

Series E in 2023
PM Pediatric Care is a specialized urgent care provider focusing on children and young adults. It offers a range of services, including therapy, medication management, and psychiatric care, with a commitment to superior quality and minimal wait times. The company aims to deliver convenient, round-the-clock care for various urgent medical needs, from minor ailments to injuries, ensuring comfort and prompt attention for young patients and their families.

Y-mAbs Therapeutics

Private Equity Round in 2017
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, dedicated to developing and commercializing innovative antibody-based therapies for cancer treatment. The company is advancing several product candidates, including naxitamab, currently in Phase 2 clinical trials for pediatric patients with relapsed osteosarcoma and high-risk neuroblastoma, as well as GD2-GD3 Vaccine, also in Phase 2 for high-risk neuroblastoma. Additionally, omburtamab is under development for desmoplastic small round cell tumors and pediatric central nervous system cancers. Y-mAbs is also exploring huB7-H3 for B7-H3 positive adult solid tumors and huCD33 BsAb for hematological cancers. The company collaborates with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to enhance its antibody constructs through the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs aims to bring multiple cancer therapies to FDA approval, with a focus on reducing long-term toxicities associated with traditional chemotherapies. Its first FDA-approved product, DANYELZA, targets GD2, a marker in various neuroectoderm-derived tumors and sarcomas.

PM Pediatric Care

Venture Round in 2014
PM Pediatric Care is a specialized urgent care provider focusing on children and young adults. It offers a range of services, including therapy, medication management, and psychiatric care, with a commitment to superior quality and minimal wait times. The company aims to deliver convenient, round-the-clock care for various urgent medical needs, from minor ailments to injuries, ensuring comfort and prompt attention for young patients and their families.

Zalora

Venture Round in 2013
Zalora is an e-commerce company specializing in fashion and footwear. It operates an online platform offering a wide range of products from various international fashion labels, including Mango, Nike, and Levi's. Customers can browse and purchase items, with options for cash-on-delivery and free returns within 30 days. Zalora is known for its efficient logistics, providing speedy and reliable deliveries. It also offers fashion tips, an online magazine, and discounts. Based in Vietnam, Zalora serves multiple countries and was launched in 2012.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.